Avadel Pharmaceuticals plc (NASDAQ: AVDL) is -8.22% lower on its value in year-to-date trading and has touched a low of $9.50 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVDL stock was last observed hovering at around $12.44 in the last trading session, with the day’s gains setting it 0.52%.
Currently trading at $12.96, the stock is -0.98% and -10.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.74 million and changing 4.18% at the moment leaves the stock -15.58% off its SMA200. AVDL registered 18.25% gain for a year compared to 6-month loss of -18.80%. The firm has a 50-day simple moving average (SMA 50) of $14.5484 and a 200-day simple moving average (SMA200) of $15.3516.
The stock witnessed a -5.05% gain in the last 1 month and extending the period to 3 months gives it a -21.93%, and is 1.17% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.10% over the week and 3.80% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.25B and $95.15M in sales. Fwd P/E is 21.20. Profit margin for the company is -111.64%. Distance from 52-week low is 36.42% and -32.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-99.19%).
The EPS is expected to grow by 74.19% this year
208.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 83.46% of the company’s shares. The shares outstanding are 96.27M, and float is at 90.35M with Short Float at 12.14%. Institutions hold 79.47% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332 of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542 and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,000 shares of the company’s common stock on Jan 16 ’24 at a price of $14.50 per share for a total of $29000.0. Following the purchase, the insider now owns 80500.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 28 ’23 that McCamish Mark Anthony (Director) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 28 ’23 and was made at $14.53 per share for $1.09 million. Following the transaction, the insider now directly holds 67025.0 shares of the AVDL stock.
